Vaccine Delivery

Troybodies study shows promising results

Published in Vaccine Weekly, May 8th, 2002

Affitech has converted its option into an exclusive worldwide license for the novel vaccine delivery technology, Troybodies. The company made the decision after early investigations demonstrated the ability of the technology to elicit a specific cellular immune response in vivo.

Affitech secured an exclusive option to Troybodies from the technology's inventors at the University of Oslo and the Norwegian National Hospital. This option will now be converted to an exclusive worldwide licence with unrestricted sublicense rights. As part of the option agreement, Affitech will enter into a research and development plan with the University of Oslo on cancer and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-05-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry